Tentarix is developing biologic therapies that target specific cells in the body and could be used to fight cancer and autoimmune diseases while limiting side effects
An antibody-based drug development startup co-founded by veteran B.C. life sciences entrepreneurs has raised US$35-million from investors weeks after inking a development deal with pharma giant Gilead Sciences Inc.
The antibody-like drugs function like a combination lock, only activating targeted cells if the biologic’s tentacles bind with all the intended proteins. That means Tentarix-developed treatments could direct specific cells in specific parts of the body to do particular tasks such as killing cancer cells or proliferating white blood cells that reduce inflammations caused by autoimmune diseases while limiting side effects.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
No need for the Bank of Canada to raise rates again: CIBCBank of Canada does not need to raise its interest rate again but it might anyway. Watch CIBC economist Benjamin Tal on the economy
Lire la suite »
No need for the Bank of Canada to raise rates again: CIBCBank of Canada does not need to raise its interest rate again but it might anyway. Watch CIBC economist Benjamin Tal on the economy
Lire la suite »
Over 300 cars displayed in Kingston to help raise money for cancer researchOver 300 cars packed the Kingston Memorial Centre for the annual Limestone city car classic, an event that raises money for cancer research.
Lire la suite »
SoftBank’s Arm Seeks to Raise Up to $4.87 Billion in Anticipated IPOSoftBank Group Corp.’s Arm Holdings Ltd. is planning to raise as much as $4.87 billion in what would be the biggest initial public offering of the year, though smaller than the once-obscure designer of phone chips previously considered.
Lire la suite »